|
Gene: DDX27 |
Gene summary for DDX27 |
Gene summary. |
Gene information | Species | Human | Gene symbol | DDX27 | Gene ID | 55661 |
Gene name | DEAD-box helicase 27 | |
Gene Alias | DRS1 | |
Cytomap | 20q13.13 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96GQ7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55661 | DDX27 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.99e-09 | 4.22e-01 | -0.0811 |
55661 | DDX27 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.49e-10 | 2.74e-01 | -0.1954 |
55661 | DDX27 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.31e-02 | 1.93e-01 | -0.1464 |
55661 | DDX27 | HTA11_1391_2000001011 | Human | Colorectum | AD | 5.04e-05 | 3.66e-01 | -0.059 |
55661 | DDX27 | HTA11_866_3004761011 | Human | Colorectum | AD | 9.49e-13 | 5.13e-01 | 0.096 |
55661 | DDX27 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.14e-08 | 3.30e-01 | 0.0674 |
55661 | DDX27 | HTA11_6818_2000001021 | Human | Colorectum | AD | 7.86e-04 | 2.81e-01 | 0.0588 |
55661 | DDX27 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.50e-03 | 1.94e-01 | 0.294 |
55661 | DDX27 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.09e-03 | 3.61e-01 | 0.281 |
55661 | DDX27 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.38e-37 | 9.96e-01 | 0.3859 |
55661 | DDX27 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.13e-13 | 6.95e-01 | 0.2585 |
55661 | DDX27 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.49e-10 | 4.08e-01 | 0.3005 |
55661 | DDX27 | A001-C-119 | Human | Colorectum | FAP | 4.95e-02 | 4.40e-01 | -0.1557 |
55661 | DDX27 | A015-C-104 | Human | Colorectum | FAP | 4.68e-02 | 1.86e-01 | -0.1899 |
55661 | DDX27 | A001-C-007 | Human | Colorectum | CRC | 3.38e-12 | 8.34e-01 | 0.1899 |
55661 | DDX27 | A014-C-008 | Human | Colorectum | FAP | 3.04e-04 | 4.92e-01 | -0.191 |
55661 | DDX27 | CRC-3-11773 | Human | Colorectum | CRC | 6.13e-09 | 4.08e-01 | 0.2564 |
55661 | DDX27 | LZE4T | Human | Esophagus | ESCC | 2.54e-12 | 4.73e-01 | 0.0811 |
55661 | DDX27 | LZE5T | Human | Esophagus | ESCC | 2.87e-09 | 3.57e-01 | 0.0514 |
55661 | DDX27 | LZE7T | Human | Esophagus | ESCC | 3.63e-14 | 5.02e-01 | 0.0667 |
Page: 1 2 3 4 5 6 7 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0022613 | Colorectum | AD | ribonucleoprotein complex biogenesis | 151/3918 | 463/18723 | 1.96e-09 | 1.39e-07 | 151 |
GO:0042254 | Colorectum | AD | ribosome biogenesis | 84/3918 | 299/18723 | 1.82e-03 | 1.50e-02 | 84 |
GO:00226132 | Colorectum | MSS | ribonucleoprotein complex biogenesis | 144/3467 | 463/18723 | 2.76e-11 | 3.67e-09 | 144 |
GO:00422542 | Colorectum | MSS | ribosome biogenesis | 79/3467 | 299/18723 | 4.32e-04 | 5.23e-03 | 79 |
GO:0006364 | Colorectum | MSS | rRNA processing | 58/3467 | 225/18723 | 4.17e-03 | 3.03e-02 | 58 |
GO:0016072 | Colorectum | MSS | rRNA metabolic process | 60/3467 | 236/18723 | 5.01e-03 | 3.46e-02 | 60 |
GO:00226134 | Colorectum | FAP | ribonucleoprotein complex biogenesis | 91/2622 | 463/18723 | 4.28e-04 | 5.12e-03 | 91 |
GO:00226135 | Colorectum | CRC | ribonucleoprotein complex biogenesis | 76/2078 | 463/18723 | 3.04e-04 | 4.78e-03 | 76 |
GO:002261327 | Esophagus | HGIN | ribonucleoprotein complex biogenesis | 158/2587 | 463/18723 | 2.61e-29 | 5.23e-26 | 158 |
GO:004225426 | Esophagus | HGIN | ribosome biogenesis | 101/2587 | 299/18723 | 8.74e-19 | 4.03e-16 | 101 |
GO:001607219 | Esophagus | HGIN | rRNA metabolic process | 72/2587 | 236/18723 | 2.26e-11 | 2.56e-09 | 72 |
GO:000636419 | Esophagus | HGIN | rRNA processing | 69/2587 | 225/18723 | 4.53e-11 | 5.04e-09 | 69 |
GO:003447010 | Esophagus | HGIN | ncRNA processing | 97/2587 | 395/18723 | 5.92e-09 | 3.90e-07 | 97 |
GO:00346606 | Esophagus | HGIN | ncRNA metabolic process | 104/2587 | 485/18723 | 2.26e-06 | 8.23e-05 | 104 |
GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
GO:0016072110 | Esophagus | ESCC | rRNA metabolic process | 197/8552 | 236/18723 | 1.31e-33 | 1.18e-30 | 197 |
GO:0006364110 | Esophagus | ESCC | rRNA processing | 189/8552 | 225/18723 | 4.88e-33 | 3.87e-30 | 189 |
GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DDX27 | SNV | Missense_Mutation | rs761824316 | c.374N>A | p.Arg125Gln | p.R125Q | Q96GQ7 | protein_coding | deleterious(0.03) | probably_damaging(0.977) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DDX27 | SNV | Missense_Mutation | novel | c.2388N>T | p.Lys796Asn | p.K796N | Q96GQ7 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.987) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DDX27 | SNV | Missense_Mutation | rs749566914 | c.337N>C | p.Ala113Pro | p.A113P | Q96GQ7 | protein_coding | tolerated(0.29) | benign(0.012) | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
DDX27 | SNV | Missense_Mutation | rs749566914 | c.337G>C | p.Ala113Pro | p.A113P | Q96GQ7 | protein_coding | tolerated(0.29) | benign(0.012) | TCGA-BH-A0BG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DDX27 | SNV | Missense_Mutation | rs377559919 | c.1904N>A | p.Arg635Gln | p.R635Q | Q96GQ7 | protein_coding | tolerated(0.08) | benign(0.018) | TCGA-BH-A0DL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
DDX27 | SNV | Missense_Mutation | novel | c.635N>T | p.Ser212Phe | p.S212F | Q96GQ7 | protein_coding | deleterious(0.02) | possibly_damaging(0.798) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
DDX27 | SNV | Missense_Mutation | novel | c.1513N>A | p.Ala505Thr | p.A505T | Q96GQ7 | protein_coding | tolerated(0.38) | benign(0.255) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
DDX27 | SNV | Missense_Mutation | rs749566914 | c.337G>C | p.Ala113Pro | p.A113P | Q96GQ7 | protein_coding | tolerated(0.29) | benign(0.012) | TCGA-BH-A1FR-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
DDX27 | insertion | In_Frame_Ins | novel | c.1032_1033insTATCTAGCCTGCATTTTGCCCTCCTTGTGCTATTGGAAGTCAGAA | p.Ile344_Ala345insTyrLeuAlaCysIleLeuProSerLeuCysTyrTrpLysSerGlu | p.I344_A345insYLACILPSLCYWKSE | Q96GQ7 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
DDX27 | insertion | Frame_Shift_Ins | novel | c.960_961insGCTAATTTTTATATATTTAGTAGAGACAGGAT | p.Cys321AlafsTer20 | p.C321Afs*20 | Q96GQ7 | protein_coding | TCGA-A8-A06Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |